Supplemental Evidence and Data Request on The Effect of Dietary Digestible Carbohydrate Intake on Risk of Type 2 Diabetes, Growth, Size, and Body Composition, 2609-2611 [2024-00618]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices
express their views in writing on the
standards enumerated in the BHC Act
(12 U.S.C. 1842(c)).
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than February 15, 2024.
A. Federal Reserve Bank of Chicago
(Colette A. Fried, Assistant Vice
President) 230 South LaSalle Street,
Chicago, Illinois 60690–1414.
Comments can also be sent
electronically to
Comments.applications@chi.frb.org:
1. Northstar Financial Group, Inc.,
Bad Axe, Michigan; to acquire
Mainstreet Community Bank of Florida,
DeLand, Florida.
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2024–00691 Filed 1–12–24; 8:45 am]
ddrumheller on DSK120RN23PROD with NOTICES1
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
The notificants listed below have
applied under the Change in Bank
Control Act (Act) (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
applications are set forth in paragraph 7
of the Act (12 U.S.C. 1817(j)(7)).
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in paragraph 7 of
the Act.
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Jkt 262001
[FR Doc. 2024–00692 Filed 1–12–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Supplemental Evidence and Data
Request on The Effect of Dietary
Digestible Carbohydrate Intake on Risk
of Type 2 Diabetes, Growth, Size, and
Body Composition
FEDERAL RESERVE SYSTEM
18:57 Jan 12, 2024
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
Agency for Healthcare Research and
Quality
BILLING CODE P
VerDate Sep<11>2014
Washington, DC 20551–0001, not later
than January 31, 2023.
A. Federal Reserve Bank of
Philadelphia (William Spaniel, Senior
Vice President) 10 Independence Mall,
Philadelphia, Pennsylvania 19106.
Comments can also be sent
electronically to
comments.applications@phil.frb.org:
1. Kenneth R. Lehman, Fort
Lauderdale, Florida; to acquire voting
shares of Blue Ridge Bankshares, Inc.,
Charlottesville, Virginia, and thereby
indirectly acquire voting shares of Blue
Ridge Bank, National Association,
Martinsville, Virginia.
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Request for supplemental
evidence and data submission.
AGENCY:
The Agency for Healthcare
Research and Quality (AHRQ) is seeking
scientific information submissions from
the public. Scientific information is
being solicited to inform our review on
The Effect of Dietary Digestible
Carbohydrate Intake on Risk of Type 2
Diabetes, Growth, Size, and Body
Composition, which is currently being
conducted by the AHRQ’s Evidencebased Practice Centers (EPC) Program.
Access to published and unpublished
pertinent scientific information will
improve the quality of this review.
DATES: Submission Deadline on or
before February 15, 2024.
ADDRESSES:
Email submissions: epc@
ahrq.hhs.gov.
Print submissions:
Mailing Address: Center for Evidence
and Practice Improvement, Agency for
Healthcare Research and Quality,
ATTN: EPC SEADs Coordinator, 5600
Fishers Lane, Mail Stop 06E53A,
Rockville, MD 20857.
Shipping Address (FedEx, UPS, etc.):
Center for Evidence and Practice
SUMMARY:
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
2609
Improvement Agency for Healthcare
Research and Quality, ATTN: EPC
SEADs Coordinator, 5600 Fishers Lane,
Mail Stop 06E77D, Rockville, MD
20857.
FOR FURTHER INFORMATION CONTACT:
Kelly Carper, Telephone: 301–427–1656
or Email: epc@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION: The
Agency for Healthcare Research and
Quality has commissioned the
Evidence-based Practice Centers (EPC)
Program to complete a review of the
evidence for The Effect of Dietary
Digestible Carbohydrate Intake on Risk
of Type 2 Diabetes, Growth, Size, and
Body Composition. AHRQ is conducting
this review pursuant to Section 902 of
the Public Health Service Act, 42 U.S.C.
299a.
The EPC Program is dedicated to
identifying as many studies as possible
that are relevant to the questions for
each of its reviews. In order to do so, we
are supplementing the usual manual
and electronic database searches of the
literature by requesting information
from the public (e.g., details of studies
conducted). We are looking for studies
that report on The Effect of Dietary
Digestible Carbohydrate Intake on Risk
of Type 2 Diabetes, Growth, Size, and
Body Composition. The entire research
protocol is available online at: https://
effectivehealthcare.ahrq.gov/products/
effect-dietary-digestible.
This is to notify the public that the
EPC Program would find the following
information on The Effect of Dietary
Digestible Carbohydrate Intake on Risk
of Type 2 Diabetes, Growth, Size, and
Body Composition helpful:
D A list of completed studies that
your organization has sponsored for this
topic. In the list, please indicate
whether results are available on
ClinicalTrials.gov along with the
ClinicalTrials.gov trial number.
D For completed studies that do not
have results on ClinicalTrials.gov, a
summary, including the following
elements, if relevant: study number,
study period, design, methodology,
indication and diagnosis, proper use
instructions, inclusion and exclusion
criteria, primary and secondary
outcomes, baseline characteristics,
number of patients screened/eligible/
enrolled/lost to follow-up/withdrawn/
analyzed, effectiveness/efficacy, and
safety results.
D A list of ongoing studies that your
organization has sponsored for this
topic. In the list, please provide the
ClinicalTrials.gov trial number or, if the
trial is not registered, the protocol for
the study including, if relevant, a study
number, the study period, design,
E:\FR\FM\16JAN1.SGM
16JAN1
2610
Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices
methodology, indication and diagnosis,
proper use instructions, inclusion and
exclusion criteria, and primary and
secondary outcomes.
D Description of whether the above
studies constitute ALL Phase II and
above clinical trials sponsored by your
organization for this topic and an index
outlining the relevant information in
each submitted file.
Your contribution is very beneficial to
the Program. Materials submitted must
be publicly available or able to be made
public. Materials that are considered
confidential; marketing materials; study
types not included in the review; or
information on topics not included in
the review cannot be used by the EPC
Program. This is a voluntary request for
information, and all costs for complying
with this request must be borne by the
submitter.
The draft of this review will be posted
on AHRQ’s EPC Program website and
available for public comment for a
period of 4 weeks. If you would like to
be notified when the draft is posted,
please sign up for the email list at:
https://www.effectivehealthcare.
ahrq.gov/email-updates.
The review will answer the following
questions. This information is provided
as background. AHRQ is not requesting
that the public provide answers to these
questions.
Key Questions (KQ)
KQ 1: What is the association between
dietary digestible carbohydrate intake
and the incidence of type 2 diabetes
(T2D) and effect on growth, size, and
body composition (i.e., obesity,
overweight, body weight and
composition)?
PICOTS (Populations, Interventions,
Comparators, Outcomes, Timing, and
Setting)
ddrumheller on DSK120RN23PROD with NOTICES1
INCLUSION AND EXCLUSION CRITERIA BY POPULATION, INTERVENTION, COMPARATOR, OUTCOME, TIMING, SETTING/STUDY
DESIGN (PICOTS)
PICOTS
elements
Inclusion criteria
Exclusion criteria
Population .........
• Participants who are generally healthy, including participants who are determined to be
overweight/obese, women who are pregnant or
lactating.
• Age of participants:
Æ Between 2 and 9 years (before puberty) ..
Æ Between 9 and 17 years ...........................
Æ 18 years and older.
Interventions .....
• Total dietary digestible carbohydrate intake
from foods, beverages, and dietary supplements.
Æ Total dietary digestible carbohydrate intake defined as collective starch and
sugar intake; carbohydrate intake not including dietary fiber).
• A dietary pattern that quantifies the intake of
total dietary digestible carbohydrates and allows the isolation of the effect of carbohydrate
intake from the effect of the intake of other
macronutrients.
Comparators .....
• Different total dietary digestible carbohydrate
intake level(s).
Outcomes ..........
• Incidence of type 2 diabetes .............................
• Incidence of gestational diabetes.
• Surrogate markers suggesting prediabetes or
abnormal glycemia.
Æ HbA1C level.
Æ Glucose tolerance/insulin resistance/insulin sensitivity.
• Growth, size, and body composition.
Æ Body weight.
Æ BMI.
Æ Body circumference.
Æ Body composition and distribution.
Æ Classifications of underweight, healthy
weight, overweight, and obesity.
• Studies that enroll participants with diseases/health-related conditions
that impact carbohydrate absorption or metabolism including cancer
and malabsorption syndromes.
• Studies that exclusively enroll participants hospitalized with an illness or
injury.
• Studies that exclusively enroll participants with type 1 or 2 diabetes
(i.e., studies that aim to treat participants who have already been diagnosed with the endpoint outcomes of interest).
• Studies designed to induce weight loss or treat patients who are determined to be overweight and obese through energy restriction or
hypocaloric diets for the purposes of treating additional or other medical
conditions.
• Studies that exclusively enroll participants who are determined to be
undernourished, underweight, stunted, or wasted.
• Studies that enroll participants who are prebariatric or postbariatric surgery.
• Exclude participants less than 2 years old.
• Studies that do not specify the amount of total digestible carbohydrate
intake (e.g., studies that only report type or source of digestible carbohydrate).
• Studies that do not describe the entire macronutrient distribution of the
diet (i.e., studies that do not report total digestible carbohydrate, total
fat, and total protein contents of experimental or baseline diets).
• Studies that only assess digestible carbohydrate intake via infusions
(rather than the GI tract).
• Studies that primarily measure postprandial responses, as opposed to
longer term studies.
• Studies that examine food products or dietary supplements not widely
available to U.S. consumers.
• Multi-component interventions that do not isolate the effect or association of digestible carbohydrate.
• Comparison of different sources of carbohydrates without specifying the
amount of carbohydrate intake.
• Studies that do not attempt to control for the energy intake of participants such that comparisons are made on an isocaloric basis.
• Comparisons of available carbohydrate exposure should not be confounded by differences in participants’ energy intake.
• Type 1 Diabetes.
VerDate Sep<11>2014
18:57 Jan 12, 2024
Jkt 262001
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
E:\FR\FM\16JAN1.SGM
16JAN1
Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices
2611
INCLUSION AND EXCLUSION CRITERIA BY POPULATION, INTERVENTION, COMPARATOR, OUTCOME, TIMING, SETTING/STUDY
DESIGN (PICOTS)—Continued
PICOTS
elements
Inclusion criteria
Timing ...............
• Type 2 diabetes ................................................
• Minimum intervention length of 12 weeks Effect on growth, size, and body composition.
Æ Minimum intervention length of 12 weeks.
• All except hospital and acute care ....................
• Randomized controlled trials .............................
• Nonrandomized controlled trials, including
quasi-experimental and controlled before-andafter studies.
• Prospective cohort studies ................................
• Nested case-control studies ..............................
• Relevant systematic reviews, or meta-analyses
(used for identifying additional studies).
• Studies published in English only .....................
• Studies published in peer-reviewed journals ....
• Studies published at and after the year 2000 ..
Settings .............
Study design .....
Publications .......
Exclusion criteria
• Any intervention length <12 weeks.
• Hospital and acute care.
• In vitro studies, nonoriginal data (e.g., narrative reviews, scoping reviews, editorials, letters, or erratum), retrospective cohort studies, case
series, qualitative studies, cost-benefit analysis, cross-sectional (i.e.,
nonlongitudinal) studies, survey.
• Non-English language studies.
Abbreviations: BMI = body mass index; HbA1c = hemoglobin A1C; GI = gastrointestinal; KQ = Key Question; PICOTS = populations, interventions, comparators, outcomes, timing, and settings; RCT = randomized controlled trial; U.S. = United States
Dated: January 8, 2024.
Marquita Cullom,
Associate Director.
[FR Doc. 2024–00618 Filed 1–12–24; 8:45 am]
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Supplemental Evidence and Data
Request on Updating the Measurement
Criteria for AHRQ’s National
Healthcare Quality and Disparities
Report (NHQDR)
Agency for Healthcare Research
and Quality (AHRQ), HHS. ACTION:
Request for Supplemental Evidence and
Data Submission.
SUMMARY: The Agency for Healthcare
Research and Quality (AHRQ) is seeking
scientific information submissions from
the public. Scientific information is
being solicited to inform our review on
Updating the Measurement Criteria for
AHRQ’s National Healthcare Quality
and Disparities Report (NHQDR), which
is currently being conducted by the
AHRQ’s Evidence-based Practice
Centers (EPC) Program. Access to
published and unpublished pertinent
scientific information will improve the
quality of this review.
DATES: Submission Deadline on or
before February 15, 2024.
ADDRESSES:
Email submissions: epc@
ahrq.hhs.gov.
Print submissions:
Mailing Address: Center for Evidence
and Practice Improvement, Agency for
ddrumheller on DSK120RN23PROD with NOTICES1
AGENCY:
VerDate Sep<11>2014
18:57 Jan 12, 2024
Jkt 262001
Healthcare Research and Quality,
ATTN: EPC SEADs Coordinator, 5600
Fishers Lane, Mail Stop 06E53A,
Rockville, MD 20857.
Shipping Address (FedEx, UPS, etc.):
Center for Evidence and Practice
Improvement, Agency for Healthcare
Research and Quality, ATTN: EPC
SEADs Coordinator, 5600 Fishers Lane,
Mail Stop 06E77D, Rockville, MD
20857.
FOR FURTHER INFORMATION CONTACT:
Kelly Carper, Telephone: 301–427–1656
or Email: epc@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION: The
Agency for Healthcare Research and
Quality has commissioned the
Evidence-based Practice Centers (EPC)
Program to complete a review of the
evidence for Updating the Measurement
Criteria for AHRQ’s National Healthcare
Quality and Disparities Report
(NHQDR). AHRQ is conducting this
review pursuant to Section 902 of the
Public Health Service Act, 42 U.S.C.
299a.
The EPC Program is dedicated to
identifying as many studies as possible
that are relevant to the questions for
each of its reviews. In order to do so, we
are supplementing the usual manual
and electronic database searches of the
literature by requesting information
from the public (e.g., details of studies
conducted). We are looking for studies
that report on Updating the
Measurement Criteria for AHRQ’s
National Healthcare Quality and
Disparities Report (NHQDR). The entire
research protocol is available online at:
https://effectivehealthcare.ahrq.gov/
products/measurement-criteria-qdr/
protocol.
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
This is to notify the public that the
EPC Program would find the following
information on Updating the
Measurement Criteria for AHRQ’s
National Healthcare Quality and
Disparities Report (NHQDR) helpful:
D A list of completed studies that
your organization has sponsored for this
topic. In the list, please indicate
whether results are available on
ClinicalTrials.gov along with the
ClinicalTrials.gov trial number.
D For completed studies that do not
have results on ClinicalTrials.gov, a
summary, including the following
elements, if relevant: study number,
study period, design, methodology,
indication and diagnosis, proper use
instructions, inclusion and exclusion
criteria, primary and secondary
outcomes, baseline characteristics,
number of patients screened/eligible/
enrolled/lost to follow-up/withdrawn/
analyzed, effectiveness/efficacy, and
safety results.
D A list of ongoing studies that your
organization has sponsored for this
topic. In the list, please provide the
ClinicalTrials.gov trial number or, if the
trial is not registered, the protocol for
the study including, if relevant, a study
number, the study period, design,
methodology, indication and diagnosis,
proper use instructions, inclusion and
exclusion criteria, and primary and
secondary outcomes.
D Description of whether the above
studies constitute ALL Phase II and
above clinical trials sponsored by your
organization for this topic and an index
outlining the relevant information in
each submitted file.
Your contribution is very beneficial to
the Program. Materials submitted must
E:\FR\FM\16JAN1.SGM
16JAN1
]]>Agencies
[Federal Register Volume 89, Number 10 (Tuesday, January 16, 2024)]
[Notices]
[Pages 2609-2611]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-00618]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Supplemental Evidence and Data Request on The Effect of Dietary
Digestible Carbohydrate Intake on Risk of Type 2 Diabetes, Growth,
Size, and Body Composition
AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.
ACTION: Request for supplemental evidence and data submission.
-----------------------------------------------------------------------
SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) is
seeking scientific information submissions from the public. Scientific
information is being solicited to inform our review on The Effect of
Dietary Digestible Carbohydrate Intake on Risk of Type 2 Diabetes,
Growth, Size, and Body Composition, which is currently being conducted
by the AHRQ's Evidence-based Practice Centers (EPC) Program. Access to
published and unpublished pertinent scientific information will improve
the quality of this review.
DATES: Submission Deadline on or before February 15, 2024.
ADDRESSES:
Email submissions: [email protected].
Print submissions:
Mailing Address: Center for Evidence and Practice Improvement,
Agency for Healthcare Research and Quality, ATTN: EPC SEADs
Coordinator, 5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857.
Shipping Address (FedEx, UPS, etc.): Center for Evidence and
Practice Improvement Agency for Healthcare Research and Quality, ATTN:
EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville,
MD 20857.
FOR FURTHER INFORMATION CONTACT: Kelly Carper, Telephone: 301-427-1656
or Email: [email protected].
SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and
Quality has commissioned the Evidence-based Practice Centers (EPC)
Program to complete a review of the evidence for The Effect of Dietary
Digestible Carbohydrate Intake on Risk of Type 2 Diabetes, Growth,
Size, and Body Composition. AHRQ is conducting this review pursuant to
Section 902 of the Public Health Service Act, 42 U.S.C. 299a.
The EPC Program is dedicated to identifying as many studies as
possible that are relevant to the questions for each of its reviews. In
order to do so, we are supplementing the usual manual and electronic
database searches of the literature by requesting information from the
public (e.g., details of studies conducted). We are looking for studies
that report on The Effect of Dietary Digestible Carbohydrate Intake on
Risk of Type 2 Diabetes, Growth, Size, and Body Composition. The entire
research protocol is available online at: https://effectivehealthcare.ahrq.gov/products/effect-dietary-digestible.
This is to notify the public that the EPC Program would find the
following information on The Effect of Dietary Digestible Carbohydrate
Intake on Risk of Type 2 Diabetes, Growth, Size, and Body Composition
helpful:
[ssquf] A list of completed studies that your organization has
sponsored for this topic. In the list, please indicate whether results
are available on ClinicalTrials.gov along with the ClinicalTrials.gov
trial number.
[ssquf] For completed studies that do not have results on
ClinicalTrials.gov, a summary, including the following elements, if
relevant: study number, study period, design, methodology, indication
and diagnosis, proper use instructions, inclusion and exclusion
criteria, primary and secondary outcomes, baseline characteristics,
number of patients screened/eligible/enrolled/lost to follow-up/
withdrawn/analyzed, effectiveness/efficacy, and safety results.
[ssquf] A list of ongoing studies that your organization has
sponsored for this topic. In the list, please provide the
ClinicalTrials.gov trial number or, if the trial is not registered, the
protocol for the study including, if relevant, a study number, the
study period, design,
[[Page 2610]]
methodology, indication and diagnosis, proper use instructions,
inclusion and exclusion criteria, and primary and secondary outcomes.
[ssquf] Description of whether the above studies constitute ALL
Phase II and above clinical trials sponsored by your organization for
this topic and an index outlining the relevant information in each
submitted file.
Your contribution is very beneficial to the Program. Materials
submitted must be publicly available or able to be made public.
Materials that are considered confidential; marketing materials; study
types not included in the review; or information on topics not included
in the review cannot be used by the EPC Program. This is a voluntary
request for information, and all costs for complying with this request
must be borne by the submitter.
The draft of this review will be posted on AHRQ's EPC Program
website and available for public comment for a period of 4 weeks. If
you would like to be notified when the draft is posted, please sign up
for the email list at: https://www.effectivehealthcare.ahrq.gov/email-updates.
The review will answer the following questions. This information is
provided as background. AHRQ is not requesting that the public provide
answers to these questions.
Key Questions (KQ)
KQ 1: What is the association between dietary digestible
carbohydrate intake and the incidence of type 2 diabetes (T2D) and
effect on growth, size, and body composition (i.e., obesity,
overweight, body weight and composition)?
PICOTS (Populations, Interventions, Comparators, Outcomes, Timing, and
Setting)
Inclusion and Exclusion Criteria by Population, Intervention,
Comparator, Outcome, Timing, Setting/Study Design (PICOTS)
------------------------------------------------------------------------
PICOTS elements Inclusion criteria Exclusion criteria
------------------------------------------------------------------------
Population................ Participants Studies that
who are generally enroll participants
healthy, including with diseases/health-
participants who are related conditions
determined to be that impact
overweight/obese, carbohydrate
women who are absorption or
pregnant or metabolism including
lactating. cancer and
Age of malabsorption
participants:. syndromes.
[cir] Between 2 and 9 Studies that
years (before exclusively enroll
puberty). participants
[cir] Between 9 and hospitalized with an
17 years. illness or injury.
[cir] 18 years and Studies that
older.. exclusively enroll
participants with
type 1 or 2 diabetes
(i.e., studies that
aim to treat
participants who
have already been
diagnosed with the
endpoint outcomes of
interest).
Studies
designed to induce
weight loss or treat
patients who are
determined to be
overweight and obese
through energy
restriction or
hypocaloric diets
for the purposes of
treating additional
or other medical
conditions.
Studies that
exclusively enroll
participants who are
determined to be
undernourished,
underweight,
stunted, or wasted.
Studies that
enroll participants
who are prebariatric
or postbariatric
surgery.
Exclude
participants less
than 2 years old.
Interventions............. Total Studies that
dietary digestible do not specify the
carbohydrate intake amount of total
from foods, digestible
beverages, and carbohydrate intake
dietary supplements. (e.g., studies that
[cir] Total dietary only report type or
digestible source of digestible
carbohydrate intake carbohydrate).
defined as Studies that
collective starch do not describe the
and sugar intake; entire macronutrient
carbohydrate intake distribution of the
not including diet (i.e., studies
dietary fiber). that do not report
A dietary total digestible
pattern that carbohydrate, total
quantifies the fat, and total
intake of total protein contents of
dietary digestible experimental or
carbohydrates and baseline diets).
allows the isolation Studies that
of the effect of only assess
carbohydrate intake digestible
from the effect of carbohydrate intake
the intake of other via infusions
macronutrients. (rather than the GI
tract).
Studies that
primarily measure
postprandial
responses, as
opposed to longer
term studies.
Studies that
examine food
products or dietary
supplements not
widely available to
U.S. consumers.
Multi-
component
interventions that
do not isolate the
effect or
association of
digestible
carbohydrate.
Comparators............... Different Comparison
total dietary of different sources
digestible of carbohydrates
carbohydrate intake without specifying
level(s). the amount of
carbohydrate intake.
Studies that
do not attempt to
control for the
energy intake of
participants such
that comparisons are
made on an
isocaloric basis.
Comparisons
of available
carbohydrate
exposure should not
be confounded by
differences in
participants' energy
intake.
Outcomes.................. Incidence of Type 1
type 2 diabetes. Diabetes.
Incidence of
gestational diabetes.
Surrogate
markers suggesting
prediabetes or
abnormal glycemia.
[cir] HbA1C level.
[cir] Glucose
tolerance/insulin
resistance/
insulin
sensitivity.
Growth,
size, and body
composition.
[cir] Body weight.
[cir] BMI.........
[cir] Body
circumference.
[cir] Body
composition and
distribution.
[cir]
Classifications
of underweight,
healthy weight,
overweight, and
obesity.
[[Page 2611]]
Timing.................... Type 2 Any
diabetes. intervention length
<12 weeks.
Minimum
intervention length
of 12 weeks Effect
on growth, size, and
body composition.
[cir] Minimum
intervention
length of 12
weeks.
Settings.................. All except Hospital and
hospital and acute acute care.
care.
Study design.............. Randomized In vitro
controlled trials. studies, nonoriginal
data (e.g.,
Nonrandomized narrative reviews,
controlled trials, scoping reviews,
including quasi- editorials, letters,
experimental and or erratum),
controlled before- retrospective cohort
and-after studies. studies, case
Prospective series, qualitative
cohort studies. studies, cost-
Nested case- benefit analysis,
control studies. cross-sectional
Relevant (i.e.,
systematic reviews, nonlongitudinal)
or meta-analyses studies, survey.
(used for
identifying
additional studies).
Publications.............. Studies Non-English
published in English language studies.
only.
Studies
published in peer-
reviewed journals.
Studies
published at and
after the year 2000.
------------------------------------------------------------------------
Abbreviations: BMI = body mass index; HbA1c = hemoglobin A1C; GI =
gastrointestinal; KQ = Key Question; PICOTS = populations,
interventions, comparators, outcomes, timing, and settings; RCT =
randomized controlled trial; U.S. = United States
Dated: January 8, 2024.
Marquita Cullom,
Associate Director.
[FR Doc. 2024-00618 Filed 1-12-24; 8:45 am]
BILLING CODE 4160-90-P
